Samantha F. Butts, MD, MSCE Dr. Butts is Assistant Professor of Obstetrics and Gynecology, Division of Infertility and Reproductive Endocrinology, at University of Pennsylvania Medical School in Philadelphia.
David B. Seifer, MD Dr. Seifer is Co-Director of Genesis Fertility and Reproductive Medicine at Maimonides Medical Center in Brooklyn, NY, and Professor of Obstetrics, Gynecology and Reproductive Sciences at Mount Sinai School of Medicine in New York City.
In some women, day 10 FSH is elevated even after a normal day 3 value. This makes the CCCT more sensitive than basal FSH testing; it can identify women who might go unrecognized if evaluated by day 3 FSH and estradiol levels alone.
More expensive and labor-intensive than the alternatives
Interpretation of the CCCT requires that FSH and estradiol both be assessed on days 3 and 10. An elevated FSH (≥10 mIU/mL) on either day indicates diminished ovarian reserve. As with basal FSH testing, elevated estradiol (≥80 pg/mL) on day 3 is considered abnormal. The day 10 estradiol value of the CCCT reflects whether or not clomiphene citrate was administered appropriately, and should be elevated. However, the significance of the day 10 estradiol level has been debated with respect to its predictive value for pregnancy in infertile populations.8
The addition of day 10 FSH assessment improves the sensitivity of the CCCT over basal FSH measurement, but makes it a more expensive and labor-intensive test (TABLE).5,6 The CCCT involves administration of clomiphene citrate, a safe drug (though it can have side effects), and two blood draws instead of one. Nevertheless, both tests are relatively noninvasive, rapid measures of ovarian reserve.
Drawbacks of the tests
Both basal FSH testing and the CCCT are widely used, although support for their ability to predict ovarian reserve in the infertile population has been challenged recently. Newer data demonstrate that these tests are limited in their ability to predict outcome (pregnancy and response to superovulation drugs) in all but a narrow group of patients undergoing IVF. Performance is particularly limited in:
young women
women in the general infertility population who are not utilizing IVF.9-13
Additional drawbacks of basal FSH testing and the CCCT include:
significant variability of test results from cycle to cycle (intercycle variability)
limited time frame within which the tests can be performed (intracycle variability).
The basal FSH test and CCCT have high specificity (98% to 99% for each) as an assessment of reproductive performance in infertile women and generate few false-positive results.5,6 However, the high screen cutoffs that allow for such specificity come at a price: Few women will screen positive, and sensitivity of the tests is low (between 7% and 8% for basal FSH and between 25% and 40% for the CCCT). Such low sensitivity means that many women will not conceive after infertility treatment despite a normal test result.5,11 Overall, the tests are not highly informative for many women who get tested.
Once abnormal, normal results are meaningless
Once an FSH level or the CCCT has ever been abnormal, the patient has diminished ovarian reserve; normal values in subsequent menstrual cycles do not improve the odds of pregnancy with treatment.14 This fact can be a significant source of confusion and frustration for patients.
3 | GnRH agonist stimulation —no better than FSH testing
This test was developed in the search for a very sensitive assessment of ovarian reserve. It was designed to uncover subtle abnormalities in pituitary and ovarian dynamics. It involves administering a gonadotropin-releasing hormone (GnRH) agonist such as leuprolide acetate (Lupron) on day 2 or 3 of the menstrual cycle and measuring pituitary and ovarian hormone responses.5,15
One group of investigators demonstrated a correlation between stimulated estradiol levels and responsiveness during IVF,16 but other studies have shown that the test does not perform significantly better than day 3 FSH in predicting ovarian reserve.17,18
The sensitivity of GnRH agonist testing for pregnancy is moderate (32% to 89%); specificity ranges from 79% to 97%.19
4 | Inhibin-B—not helpful when used alone
This glycoprotein hormone produced by granulosa cells of developing follicles is a direct measure of ovarian reserve when assessed in the early follicular phase of the menstrual cycle.20 Women treated with IVF who have a low inhibin-B level—particularly when using cutoffs below the range of 45–80 pg/mL—have been shown to respond poorly to superovulation and have a lower pregnancy rate than women with high inhibin-B.21,22 One group of investigators demonstrated that women with clinical evidence of diminished ovarian reserve but a normal FSH level also had low inhibin-B production, suggesting that it may be a more sensitive marker than FSH.22
Inhibin-B testing involves a simple blood draw. However, the test has been incorporated into clinical assessment of ovarian reserve only to a limited degree, due to the lack of reliable assays and controversy concerning its prognostic value.23
Because of these limitations, routine testing of serum inhibin-B in isolation of other markers of ovarian reserve is not recommended.